Status:
COMPLETED
ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
University of Colorado, Denver
AdventHealth Translational Research Institute
Conditions:
Hypertension
Aging
Eligibility:
All Genders
60+ years
Phase:
PHASE2
Brief Summary
The purpose of this project is to conduct a randomized, controlled trial (RCT) to determine if choice of antihypertensive medication influences changes in functional status and other cardiovascular ri...
Detailed Description
The purpose of this project is to conduct a randomized, controlled trial (RCT) to determine if choice of antihypertensive medication influences changes in functional status and other cardiovascular ri...
Eligibility Criteria
Inclusion
- Age 60 years and older
- Hypertension - untreated (SBP ≥ 140 mm Hg or DBP ≥ 90 mm Hg) or treated
- \> 290 seconds needed to complete long-distance corridor walk test
- Sedentary lifestyle, defined as \<150 min/wk of moderate physical activity
- Willingness to participate in all study procedures, including allowing study team to communicate with primary care physician regarding changes in antihypertensive treatment
Exclusion
- BP \> 140/90, despite the use of three or more anti-hypertensive drugs
- SBP \> 180 mm Hg or DBP \> 110 mm Hg
- Chronic kidney disease
- Serum creatinine \>2.5 mg/dL in men or \>2.0 mg/dL in women
- Serum potassium outside normal reference range
- Urinary protein \> 1 on dipstick
- Abnormal liver enzymes (AST, ALT, or alkaline phosphatase \> 2.5 times the upper limit of normal)
- Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina
- Acute myocardial infarction identified by ECG
- Significant cognitive impairment, defined as a known diagnosis of dementia or a Mini-Mental State Examination exam score \< 24;
- Simultaneous participation in another intervention trial
- Known hypersensitivity to ACE inhibitors (exclusion only to perindopril arm; will be randomized among other two interventions)
- Any other condition that would preclude participating based upon judgement of PI or study clinician team
Key Trial Info
Start Date :
May 29 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 19 2024
Estimated Enrollment :
223 Patients enrolled
Trial Details
Trial ID
NCT03295734
Start Date
May 29 2018
End Date
September 19 2024
Last Update
July 22 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
UAB Center for Exercise Medicine
Birmingham, Alabama, United States, 35205
2
Translational Research Institute
Orlando, Florida, United States, 32804